Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

'Brain fever' coverIn 'Brain Fever: How Vaccines Prevent Meningitis and Other Killer Diseases' (World Scientific 2021), which is due to be published later this summer, Professor Richard Moxon, Jesus College Emeritus Fellow and Emeritus Professor at the Department of Paediatrics, focuses on the condition that has directed his career and research over the past fifty years; research that has ultimately led to a vaccine that prevents serious illness and saves lives.

The term 'brain fever' was used widely in nineteenth century literature to describe a potentially life-threatening illness of the brain brought about by a severe emotional upset. Flick through the novels of Bram Stoker, Dostoyevsky or Sir Arthur Conan-Doyle and you'll see 'brain fever' applied to characters in various states of nervous exhaustion. However, the popular Victorian phrase more generally applied to serious medical conditions of the brain, such as encephalitis, scarlet fever, cerebritis and meningitis

Meningitis is an infection of the protective membranes that surround the brain and spinal cord (meninges). It can affect anyone, but is most common in babies, young children, teenagers and young adults. If not treated quickly, the infection can become very serious, causing life-threatening blood poisoning (septicaemia) and result in permanent damage to the brain or nerves. As a paediatrician, Richard has been on the front line in terms of providing intensive medical care for children with bacterial meningitis, and witnessed the devastation it causes.

He begins his new book by describing his boyhood dream to study medicine. He traces his career from medical student through to becoming Action Research Professor of Paediatrics at the University of Oxford and founding the now world-famous Oxford Vaccine Group (OVG).  He describes how a combination of clinical practice and laboratory science over several decades was needed to unlock the secrets of the virulent bacteria that cause the deadly disease, and how meningitis vaccines brought about a historical breakthrough in public health.

Richard pursued his medical studies at Cambridge and St Thomas’ Hospital (1960-1966). In 1970, an American colleague persuaded him to apply to be a trainee at Boston Children’s Hospital, part of the Harvard Medical School, an experience that shaped his career. There, he met clinician scientists pursuing ground-breaking research and decided to extend his stay to do research on infectious diseases of children.

In 1974, Richard was recruited to Johns Hopkins Hospital in Baltimore as Assistant Professor. He worked as a clinical infectious diseases specialist while continuing his research on H. influenzae type b (Hib) meningitis. Working in collaboration with Nobel Laureate, Hamilton Smith, Richard was one of the first to apply molecular genetics to infectious diseases and apply it to clinical practice, vaccine development, and public health. In 1979, he became the Head of Paediatric Infectious Diseases Division in the Johns Hopkins Children’s Centre.

Richard and his family moved to Oxford in 1984, where he was appointed Professor and Chair of Paediatrics at the University of Oxford. He was able to share his infectious disease expertise in child health which, at the time, was a non-existent medical specialty in the UK. Continuing his research, he was asked by the late Sir David Weatherall to be one of the founding scientists of the Institute of Molecular Medicine. He also set up the OVG, which is now one of the largest university-based paediatric clinical trials units in the world.

During this time, Richard led UK trials of the Hib meningitis vaccine. In his laboratory, he pioneered the application of genome sequencing into vaccine development, a technology that resulted, through collaboration with US and Italian scientists, in a vaccine against meningococcal meningitis that is now a routine immunisation for infants. There is no doubt that this pioneering work has been responsible for saving thousands of lives globally every year, and preventing even more cases of devastating brain damage.

Richard MoxonRichard says, "Scientists, especially the medical profession, have a special responsibility — one we have been failing to shoulder adequately for several years — to help people understand the importance of vaccines and why they are so essential for the maintenance of public health. If what is involved in developing a vaccine and how it works are not understood, trust in immunisation is compromised. 

As we are learning from the Covid-19 pandemic, it is vaccines that we rely on to fight and overcome the devastation caused by virulent germs. The message is clear: no intervention in the history of medicine has conferred a greater public health benefit than immunisation."

He adds, "It is for this reason that I have written a book that I hope will appeal to all who are curious about what is involved in developing a vaccine: the complexity of the laboratory investigations, the role of universities in supporting medical science, the challenges of obtaining research funding and, inevitably, engagement with politicians. I hope what also comes across is the sense of collaboration involved in such work, and my admiration for the brilliant scientists I have worked with over the past fifty years."

Since his retirement from the Chair of Paediatrics in the Oxford Medical School in 2005, Richard has continued to be involved in vaccine development, working on scientific advisory committees, teaching in international vaccine courses and mentoring young scientists. He has also focused on writing for more general audiences. As well writing 'Brain Fever', Richard also has a blog - MoxForum - which aims to capture a scientific perspective on key research topics, such as the COVID-19 pandemic, that strikes a middle way between esoteric scientific articles and the often over-simplified information gleaned from the media.

For more information on Brain Fever and to order your copy click here.

All royalties from the book will go to support UK Meningitis charities Meningitis Research Foundation and Meningitis Now.

Similar stories

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

How do childhood vaccination policies vary across the world?

Read about the topic in Samantha Vanderslott's latest publication.

Oxford vaccine stimulates broad antibody and T cell functions

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.

Oxford University breakthrough on global COVID-19 vaccine

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Oxford coronavirus vaccine produces strong immune response in older adults

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

SIMON Says…

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.